Romidepsin | FR 901228 | HDAC Inhibitor | AmBeed-信号通路专用抑制剂

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

产品名称	HD1 ↓ ↑	HD2 ↓ ↑	HDAC ↓ ↑	HDAC1 ↓ ↑	HDAC10 ↓ ↑	HDAC11 ↓ ↑	HDAC2 ↓ ↑	HDAC3 ↓ ↑	HDAC4 ↓ ↑	HDAC5 ↓ ↑	HDAC6 ↓ ↑	HDAC7 ↓ ↑	HDAC8 ↓ ↑	HDAC9 ↓ ↑	其他靶点	纯度
Givinostat HCl monohydrate	++++ HD1-B, IC50: 7.5 nM HD1-A, IC50: 16 nM	+++ HD2, IC50: 10 nM														99%+
MC1568	++ HD1-B (Maize), IC50: 3.4 μM HD1-A (Maize), IC50: 100 nM															96%
Trichostatin A			++++ HDAC, IC50: ~1.8 nM													99%+
Scriptaid			✔													99%+
Valproic acid sodium			✔												Autophagy	97%
AR-42			+++ HDAC, IC50: 30 nM													99%+
Dacinostat			+++ HDAC, IC50: 32 nM													98+%
CUDC-101			++++ HDAC, IC50: 4.4 nM	++++ HDAC1, IC50: 4.5 nM	+++ HDAC10, IC50: 26.1 nM		+++ HDAC2, IC50: 12.6 nM	++++ HDAC3, IC50: 9.1 nM	+++ HDAC4, IC50: 13.2 nM	+++ HDAC5, IC50: 11.4 nM	++++ HDAC6, IC50: 5.1 nM	+ HDAC7, IC50: 373 nM	++ HDAC8, IC50: 79.8 nM	++ HDAC9, IC50: 67.2 nM	EGFR,HER2	99%+
M344			++ HDAC, IC50: 100 nM													99%+
Splitomicin			+ Sir2p, IC50: 60 μM													99%
Panobinostat			++++ HDAC (Reh cells), IC50: 20 nM HDAC (MOLT-4 cells), IC50: 5 nM													98%
Sodium 4-Phenylbutyrate			✔													98%
Vorinostat			+++ HDAC, IC50: ~10 nM													98%
Curcumin			✔												Nrf2,NF-κB	98%
Belinostat			+++ HDAC, IC50: 27 nM													98%
RG-2833				++ HDAC1, Ki: 32 nM				++ HDAC3, Ki: 5 nM								98%
Valproic acid				+ HDAC1, IC50: 0.4 mM												98%
BG45				+ HDAC1, IC50: 2 μM			+ HDAC2, IC50: 2.2 μM	+ HDAC3, IC50: 289 nM								99%+
Entinostat				+ HDAC1, IC50: 0.51 μM				+ HDAC3, IC50: 1.7 μM								98%
Resminostat				+++ HDAC1, IC50: 42.5 nM				++ HDAC3, IC50: 50.1 nM			++ HDAC6, IC50: 71.8 nM					98+%
Romidepsin				+++ HDAC1, IC50: 36 nM			+++ HDAC2, IC50: 47 nM									99%+
Parthenolide				✔											NF-κB,p53	97% HPLC
Tacedinaline				+ HDAC1, IC50: 0.9 μM			+ HDAC2, IC50: 0.9 μM	+ HDAC3, IC50: 1.2 μM								98%
Mocetinostat				++ HDAC1, IC50: 0.15 μM		+ HDAC11, IC50: 0.59 μM	+ HDAC2, IC50: 0.29 μM	+ HDAC3, IC50: 1.66 μM								98%
WT-161				++++ HDAC1, IC50: 8.35 nM			+++ HDAC2, IC50: 15.4 nM				++++ HDAC6, IC50: 0.4 nM					99%+
Fimepinostat				++++ HDAC1, IC50: 1.7 nM	++++ HDAC10, IC50: 2.8 nM	++++ HDAC11, IC50: 5.4 nM	++++ HDAC2, IC50: 5.0 nM	++++ HDAC3, IC50: 1.8 nM			+++ HDAC6, IC50: 27 nM					99%+
Tucidinostat				++ HDAC1, IC50: 95 nM	++ HDAC10, IC50: 78 nM		++ HDAC2, IC50: 160 nM	++ HDAC3, IC50: 67 nM								99%+
Santacruzamate A							++++ HDAC2, IC50: 119 pM									99%+
(E,E)-RGFP966								++ HDAC3, IC50: 80 nM								99%+
LMK-235									+++ HDAC4, IC50: 11.9 nM	++++ HDAC5, IC50: 4.2 nM						99%+
Tasquinimod									✔							99%+
CAY10603											++++ HDAC6, IC50: 2 pM					98%
Tubastatin A											+++ HDAC6, IC50: 15 nM					98%
Tubacin											++++ HDAC6, IC50: 4 nM					99%+
ACY-738											++++ HDAC6, IC50: 1.7 nM					99%+
Nexturastat A											++++ HDAC6, IC50: 5 nM					99%+
BRD73954											+++ HDAC6, IC50: 36 nM		++ HDAC8, IC50: 120 nM			99%
Tubastatin A HCl											+++ HDAC6, IC50: 15 nM		+ HDAC8, IC50: 854 nM			98%
PCI-34051													+++ HDAC8, IC50: 10 nM			99%+
Ricolinostat				++ HDAC1, IC50: 58 nM			++ HDAC2, IC50: 48 nM	++ HDAC3, IC50: 51 nM			++++ HDAC6, IC50: 4.7 nM		++ HDAC8, IC50: 100 nM			99%+
Droxinostat								+ HDAC3, IC50: 16.9 μM			+ HDAC6, IC50: 2.47 μM		+ HDAC8, IC50: 1.46 μM			99%+
Abexinostat				++++ HDAC1, Ki: 7 nM	+++ HDAC10, IC50: 24 nM		+++ HDAC2, Ki: 19 nM	++++ HDAC3/SMRT, Ki: 8.2 nM			+++ HDAC6, Ki: 17 nM		+ HDAC8, IC50: 280 nM			98%+
Citarinostat				+++ HDAC1, IC50: 35 nM			+++ HDAC2, IC50: 45 nM	+++ HDAC3, IC50: 46 nM			++++ HDAC6, IC50: 2.6 nM		++ HDAC8, IC50: 137 nM			99%+
HPOB				+ HDAC1, IC50: 2.9 μM	+ HDAC10, IC50: 3.0 μM		+ HDAC2, IC50: 4.4 μM	+ HDAC3, IC50: 1.7 μM			++ HDAC6, IC50: 56 nM		+ HDAC8, IC50: 2.8 μM			97%
Quisinostat 2HCl				++++ HDAC1, IC50: 0.11 nM	++++ HDAC10, IC50: 0.46 nM	++++ HDAC11, IC50: 0.37 nM	++++ HDAC2, IC50: 0.33 nM	++++ HDAC3, IC50: 4.86 nM	++++ HDAC4, IC50: 0.64 nM	++++ HDAC5, IC50: 3.69 nM			++++ HDAC8, IC50: 4.26 nM			97%
Domatinostat				+ HDAC1, IC50: 1.20 μM	+ HDAC10, IC50: 21 μM	+ HDAC11, IC50: 9.7 μM	+ HDAC2, IC50: 1.12 μM	+ HDAC3, IC50: 0.57 μM		+ HDAC5, IC50: 11.3 μM				+ HDAC9, IC50: 50 μM		99%+
TMP269									++ HDAC4, IC50: 157 nM	++ HDAC5, IC50: 97 nM		+++ HDAC7, IC50: 43 nM		+++ HDAC9, IC50: 23 nM		99%+
Pracinostat				++ HDAC1, IC50: 49 nM	+++ HDAC10, IC50: 40 nM	++ HDAC11, IC50: 93 nM	++ HDAC2, IC50: 96 nM	+++ HDAC3, IC50: 43 nM	++ HDAC4, IC50: 56 nM	+++ HDAC5, IC50: 47 nM	+ HDAC6, IC50: 1.008 μM	++ HDAC7, IC50: 137 nM	++ HDAC8, IC50: 140 nM	++ HDAC9, IC50: 70 nM		99%+
TMP195									++ HDAC4, Ki: 59 nM	++ HDAC5, Ki: 60 nM		+++ HDAC7, Ki: 26 nM		+++ HDAC9, Ki: 15 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Cell Line BR MM cells CD4 T cells HEK293T/17 cells HAP1-ABEdox:GFP reporter cells RT112 MBT2 HT1376 HCT116 colon cancer cells PBMC from healthy donors PBMC from healthy donors PBMC from healthy donors	Concentration	Treated Time	Description	References
BR MM cells	100 nM	24 h	Evaluate the sensitivity of Romidepsin combined with BTZ in BR MM cells, results showed that the combination significantly increased the apoptosis rate	Nat Commun. 2023 Mar 9;14(1):1290.
CD4 T cells	0.15nM-640nM	4 h	To measure the ability of Romidepsin to induce histone H4 acetylation in different CD4 T cell subsets, results showed that Romidepsin exhibited higher potency in T EM cells.	Cell Rep. 2019 Nov 26;29(9):2783-2795.e5.
HEK293T/17 cells	10 nM	72 h	Romidepsin increased the base editing efficiency mediated by ABE7.10, particularly at the A5 position of the CCR5 target site, where the A:T to G:C substitution frequency increased from 10.7% to 37.9%.	Nucleic Acids Res. 2021 Feb 26;49(4):2390-2399.
HAP1-ABEdox:GFP reporter cells	10 nM	48 h	Romidepsin significantly increased GFP expression levels, and at the A6 position of the EGFP target site, the A:T to G:C substitution frequency increased from 37.9% to 72.9%.	Nucleic Acids Res. 2021 Feb 26;49(4):2390-2399.
RT112	2.5 nM, 5 nM	24 h	To evaluate the cytotoxicity and radiosensitizing effects of Romidepsin, results showed that Romidepsin was effective in the nanomolar range and significantly enhanced the sensitivity of bladder cancer cells to ionizing radiation.	Int J Radiat Oncol Biol Phys. 2020 May 1;107(1):212-221.
MBT2	0.6 nM, 2 nM	24 h	To evaluate the cytotoxicity and radiosensitizing effects of Romidepsin, results showed that Romidepsin was effective in the nanomolar range and significantly enhanced the sensitivity of bladder cancer cells to ionizing radiation.	Int J Radiat Oncol Biol Phys. 2020 May 1;107(1):212-221.
HT1376	0.4 nM, 0.6 nM	24 h	To evaluate the cytotoxicity and radiosensitizing effects of Romidepsin, results showed that Romidepsin was effective in the nanomolar range and significantly enhanced the sensitivity of bladder cancer cells to ionizing radiation.	Int J Radiat Oncol Biol Phys. 2020 May 1;107(1):212-221.
HCT116 colon cancer cells	50 nM	24 h	To evaluate the effect of Romidepsin on type I IFN signaling in HCT116 cells	EMBO Rep. 2020 Jun 4;21(6):e50162.
PBMC from healthy donors	50 ng/ml	24 h	Romidepsin significantly suppressed the cytotoxicity of NK cells from healthy donors (untreated median=22.65%, romidepsin median= 13.4%; P=.0069). However, cytokine stimulation with IL-12 and IFN- γ significantly increased the cytolytic activity of these healthy NK cells even in romidepsin treated cells (unstimulated median= 13.4%, IL-12 & IFN-α stimulated median= 20.7%; P=.0051).	Am J Hematol. 2012 Apr;87(4):354-60.
PBMC from healthy donors	50 ng/ml	48 h	Romidepsin treatment significantly decreased CD80 expression in these stimulated cells (non-romidepsin treated median= 72.2%, romidepsin treated median= 33.45%; P= .0277).	Am J Hematol. 2012 Apr;87(4):354-60.
PBMC from healthy donors	50 ng/ml	48 h	Romidepsin treatment significantly decreased the in vitro production of IL-12 (untreated median= 676, romidepsin treated median= 31; P= .0077).	Am J Hematol. 2012 Apr;87(4):354-60.

Species NSG mice Mice Mice Mice	Animal Model WiT49-PRC-1 tumor model NSG xenograft model SU-DHL-10 xenograft model CD1-nude mice	Administration	Dosage	Frequency	Description	References
NSG mice	WiT49-PRC-1 tumor model	Intraperitoneal injection	4 mg/kg	Daily, for 16 days	Romidepsin strongly inhibited the growth of WiT49-PRC-1 tumors and effectively blocked their metastasis to the liver and lung.	Cell Rep Med. 2024 Oct 15;5(10):101770
Mice	NSG xenograft model	Intraperitoneal injection	1 mg/kg	Every 2 days, continuous treatment	Evaluate the anti-tumor effect of Romidepsin combined with BTZ in BR MM cell xenograft model, results showed that the combination significantly suppressed tumor growth and improved the survival rate of mice	Nat Commun. 2023 Mar 9;14(1):1290.
Mice	SU-DHL-10 xenograft model	Intraperitoneal injection	2 mg/kg	Administered on days 1, 8, 15	To evaluate the in vivo efficacy of Romidepsin in combination with GSK126, results showed significant tumor growth delay and improved overall survival	Clin Cancer Res. 2019 Sep 1;25(17):5271-5283
Mice	CD1-nude mice	Intraperitoneal injection	4 mg/kg	Single injection	To evaluate the radiosensitizing effects of Romidepsin in vivo, results showed that Romidepsin combined with ionizing radiation significantly delayed tumor growth without increasing acute or late intestinal and bladder toxicity.	Int J Radiat Oncol Biol Phys. 2020 May 1;107(1):212-221.

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02661178	Healthy Volunteers	Phase 1	Completed	-	United Kingdom ... 展开 >> Hammersmith Medicines Research London, United Kingdom, NW10 7EW 收起 <<
NCT01663571	-		Terminated(Study is permanentl... 展开 >>y closed to enrollment .Collection of private identifiable information is complete Analysis of private identifiable information is complete) 收起 <<	-	United States, New York ... 展开 >> NYU Langone Medical Center New York, New York, United States, 10016 收起 <<
NCT03432741	Breast Adenocarcinoma ... 展开 >> Recurrent Breast Carcinoma Recurrent Hodgkin Lymphoma Recurrent Mycosis Fungoides Recurrent Non-Hodgkin Lymphoma Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Refractory Hodgkin Lymphoma Refractory Mycosis Fungoides Refractory Nodal Marginal Zone Lymphoma Refractory Non-Hodgkin Lymphoma Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Stage IV Breast Cancer AJCC v6 and v7 收起 <<	Phase 1	Recruiting	May 1, 2019	United States, Minnesota ... 展开 >> Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Grzegorz S. Nowakowski 收起 <<
NCT03593018	Relapsed Angioimmunoblastic T-... 展开 >>Cell Lymphoma Refractory Angioimmunoblastic T-cell Lymphoma 收起 <<	Phase 3	Recruiting	December 2021	Belgium ... 展开 >> A. Z. Sint-Jan Brugge-Oostende AV Recruiting Bruges, Belgium Contact: Sylvia SNAUWAERT, MD Cliniques Universitaires de Bruxelles - Hôpital Erasme Recruiting Bruxelles, Belgium Contact: Alice WOLFROMM, MD Université Catholique de Louvain Saint-Luc Recruiting Bruxelles, Belgium Contact: Nicole STRAETMANS, MD CHU de Liège Recruiting Liège, Belgium Contact: Christophe BONNET, MD CHU UCL Namur - Site Godinne Recruiting Yvoir, Belgium Contact: Marc ANDRE, MD France Institut d'Hématologie de Basse Normandie Recruiting Caen, France Contact: Gandhi DAMAJ, MD CHU de Clermont-Ferrand - Hôpital Estaing Recruiting Clermont-Ferrand, France Contact: Olivier TOURNILHAC, MD CHU Henri Mondor Recruiting Créteil, France Contact: Jehan DUPUIS, MD CHU de Dijon Recruiting Dijon, France Contact: Olivier CASASNOVAS, MD CHU de Grenoble Recruiting Grenoble, France Contact: Rémy GRESSIN, MD CHRU de Lille Recruiting Lille, France Contact: Franck MORSCHHAUSER, MD CHU de Limoges Recruiting Limoges, France Contact: Céline KENNEL, MD CHU de Montpellier - Hôpital Saint-Eloi Recruiting Montpellier, France Contact: Guillaume CARTRON, MD CHU de Nantes - Hôtel Dieu Recruiting Nantes, France Contact: Steven LE GOUILL, MD Hôpital Necker Recruiting Paris, France Contact: Richard DELARUE, MD Hôpital Saint-Louis Recruiting Paris, France Contact: Catherine THIEBLEMONT, MD CHU Haut-Lévèque - Centre François Magendie Recruiting Pessac, France Contact: Kamal BOUABDALLAH, MD CHU Lyon-Sud Recruiting Pierre-Bénite, France Contact: Emmanuel BACHY, MD CH Annecy Genevois Recruiting Pringy, France Contact: Nicolas DAGUINDAU, MD CHU Pontchaillou Recruiting Rennes, France Contact: Roch HOUOT, MD Centre Henri Becquerel Recruiting Rouen, France Contact: Hervé TILLY, MD IUCT - Oncopole Recruiting Toulouse, France Contact: Loïc YSEBAERT, MD CHRU de Nancy - Hôpital de Brabois Recruiting Vandœuvre-lès-Nancy, France Contact: Lauriane CLEMENT-FILLIATRE, MD 收起 <<
NCT03703375	Lymphoma, T-Cell	Phase 3	Not yet recruiting	December 31, 2021	Japan ... 展开 >> National Hospital Organization Nagoya Medical Center Not yet recruiting Nagoya, Aichi, Japan National Cancer Center Hospital East Not yet recruiting Kashiwa, Chiba, Japan Kyushu University Hospital Not yet recruiting Higashi-ku, Fukuoka, Japan University of Tsukuba Hospital Not yet recruiting Tsukuba, Ibataki, Japan Tokai University Hospital Not yet recruiting Isehara, Kanagawa, Japan National University Corporation Tohoku University Hospital Not yet recruiting Sendai, Miyagi, Japan Kindai University Hospital Not yet recruiting Osaka-Sayama, Osaka, Japan Saitama Medical University International Medical Center Not yet recruiting Hidaka, Saitama, Japan National Cancer Center Hospital Not yet recruiting Chuo-ku, Tokyo, Japan The Cancer Institute Hospital of Japanese Foundation For Cancer Research Not yet recruiting Koto-ku, Tokyo, Japan 收起 <<
NCT02551718	Acute Leukemia of Ambiguous Li... 展开 >>neage Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Refractory Adult Acute Lymphoblastic Leukemia Refractory Childhood Acute Lymphoblastic Leukemia 收起 <<	Not Applicable	Recruiting	-	United States, Washington ... 展开 >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Pamela S. Becker 206-616-1589 pbecker@u.washington.edu Principal Investigator: Pamela S. Becker 收起 <<
NCT02788201	Urothelial Carcinoma ... 展开 >> Bladder Cancer Urinary Bladder Neoplasms 收起 <<	Phase 2	Recruiting	July 1, 2020	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 收起 <<
NCT00037817	Advanced Esophageal Cancers ... 展开 >> Primary Small Cell Lung Cancers Non-Small-Cell Lung Carcinoma Pleural Mesotheliomas Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01482962	-		Completed	-	-
NCT01482962	Relapsed Peripheral T-Cell Lym... 展开 >>phoma Refractory Peripheral T-Cell Lymphoma 收起 <<	Phase 3	Completed	-	-
NCT00094978	Carcinoma, Small Cell ... 展开 >> Carcinoma, Non-Small-Cell Lung Esophageal Neoplasms Mesothelioma 收起 <<	Phase 1	Terminated	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT00299351	Peripheral T Cell Lymphoma (PT... 展开 >>CL) 收起 <<	Phase 2	Unknown	-	-
NCT02512172	Colorectal Cancer	Phase 1	Recruiting	January 2019	United States, Maryland ... 展开 >> Johns Hopkins Recruiting Baltimore, Maryland, United States, 21205 Principal Investigator: Nilofer Azad, MD 收起 <<
NCT03619278	HIV Infections	Phase 1 Phase 2	Not yet recruiting	July 15, 2020	-
NCT00020202	Extensive Stage Small Cell Lun... 展开 >>g Cancer Stage IIIA Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer Recurrent Small Cell Lung Cancer Stage IIIB Non-small Cell Lung Cancer Recurrent Non-small Cell Lung Cancer 收起 <<	Phase 2	Completed	-	United States, Maryland ... 展开 >> Surgery Branch Bethesda, Maryland, United States, 20892 收起 <<
NCT00079443	Recurrent Grade 1 Follicular L... 展开 >>ymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Small Lymphocytic Lymphoma 收起 <<	Phase 2	Terminated	-	United States, Maryland ... 展开 >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201-1595 收起 <<
NCT02223208	Peripheral T-cell Lymphomas (P... 展开 >>TCL) PTCL-NOS Angioimmunoblastic T-cell Lymphoma (AITL) ALK- Anaplastic Large Cell Lymphoma (ALCL) 收起 <<	Phase 1 Phase 2	Recruiting	March 2025	Italy ... 展开 >> Ospedale SS. Antonio e Biagio e Cesare Arrigo Recruiting Alessandria, AL, Italy, 15121 Contact: Manuela Zanni, MD 0039 0131206133 manuela.zanni@ospedale.al.it Principal Investigator: Flavia Salvi, MD Ospedali Riuniti Umberto I Not yet recruiting Ancona, AN, Italy, 60126 Contact: Attilio Olivieri, PROF 0039 0715964226 a.olivieri@unipm.it Principal Investigator: Attilio Olivieri, PROF AOU Policlinico di Bari Not yet recruiting Bari, BA, Italy, 70124 Contact: Giorgina Specchia, PROF 0039 0805593471 giorgina.specchia@uniba.it Principal Investigator: Giorgina Specchia, PROF Policlinico S. Orsola Malpighi Recruiting Bologna, BO, Italy, 40138 Contact: Vittorio Stefoni, MD 0039 0516364042 vittorio.stefoni2@unibo.it Principal Investigator: Vittorio Stefoni, MD Spedali Civili Recruiting Brescia, BS, Italy, 26123 Contact: Alessandro Re, MD 0039 0303995438 ematologia@spedalicivili.it Principal Investigator: Alessandro Re, MD Ospedale Businco Recruiting Cagliari, CA, Italy, 09121 Contact: Giuseppina Cabras, MD 0039 0706095171 cabras.giuseppina@tiscali.it Principal Investigator: Giuseppina Cabras, MD Fondazione di Ricerca e Cura "Giovanni Paolo II" Not yet recruiting Campobasso, CB, Italy, 86100 Contact: Sergio Storti, MD 0039 0874312317 sstorti@rm.unicatt.it Principal Investigator: Sergio Storti, MD Azienda Ospedaliera S.Croce e Carle Recruiting Cuneo, CN, Italy, 12100 Contact: Claudia Castellino, MD 0039 0171641070 castellino.c@ospedale.cuneo.it Principal Investigator: Claudia Castellino, MD Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Sede di Meldola Not yet recruiting Meldola, FC, Italy, 47014 Contact: Gerardo Musuraca, MD 0039 0543739280 g.musuraca@irst.em.it Principal Investigator: Gerardo Musuraca, MD IRCCS Casa Sollievo Della Sofferenza Not yet recruiting San Giovanni Rotondo, FG, Italy, 71013 Contact: Nicola Cascavilla, MD 0039 0882410566 ematologia@operapadrepio.it Principal Investigator: Nicola Cascavilla, MD IRCCS AOU San Martino - Clinica Ematologica Not yet recruiting Genova, GE, Italy, 16321 Contact: Filippo Ballerini, PROF 0039 0105554336 ballerini@unige.it Principal Investigator: Filippo Ballerini, PROF IRCCS AOU San Martino - UO Ematologia 1 Recruiting Genova, GE, Italy, 16321 Contact: Angela Giovanna Congiu, MD 0039 0105513731 angelagiovanna.congiu@hsanmartino.it Principal Investigator: Angela Giovanna Congiu, MD Istituto Clinico Humanitas Terminated Rozzano, Milano, Italy, 20089 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Recruiting Milano, MI, Italy, 20122 Contact: Luca Baldini, MD 0039 02 55033334 luca.baldini@unimi.it Principal Investigator: Luca Baldini, PROF Fondazione IRCCS "Istituto Nazionale dei Tumori" Recruiting Milano, MI, Italy, 20133 Contact: Paolo Corradini, PROF 0039 0223902950 paolo.corradini@unimi.it Principal Investigator: Paolo Corradini, PROF Azienda Ospedaliera Ospedale Niguarda Ca' Granda Recruiting Milano, MI, Italy, 20162 Contact: Chiara Rusconi, MD 0039 02 64447597 chiara.rusconi@ospedaleniguarda.it Principal Investigator: Chiara Rusconi, MD AO Ospedali Riuniti Villa Sofia - Cervello (Presidio Cervello) Not yet recruiting Palermo, PA, Italy, 90146 Contact: Caterina Patti, MD 0039 0917803162 kpatti@ospedaliriunitipalermo.it Principal Investigator: Caterina Patti, MD P.O. di Pescara-Ospedale Civile Spirito Santo Not yet recruiting Pescara, PE, Italy, 65126 Contact: Francesco Angrilli, MD 0039 0854252838 f.angrilli@virgilio.it Principal Investigator: Francesco Angrilli, MD IRCCS Centro di Riferimento Oncologico (CRO) Not yet recruiting Aviano, PN, Italy, 33081 Contact: Michele Spina, MD 0039 043459730 mspina@cro.it Principal Investigator: Michele Spina, MD AOU di Parma Not yet recruiting Parma, PR, Italy, 43100 Contact: Francesca Re, MD 0039 0521 703962 fre@ao.pr.it Principal Investigator: Francesca Re, MD Fondazione IRCCS - Policlinico San Matteo Recruiting Pavia, PV, Italy, 27100 Contact: Luca Arcaini, MD 0039 0382501381 luca.arcaini@unipv.it Principal Investigator: Luca Arcaini, MD IRCCS Centro di Riferimento Oncologico della Basilicata (CROB) Not yet recruiting Rionero in Vulture, PZ, Italy, 85028 Contact: Roberto Guariglia, MD 0039 0972726225 robertoguariglia@libero.it Principal Investigator: Roberto Guariglia, MD A.O. Bianchi - Melacrino - Morelli Not yet recruiting Reggio Calabria, RC, Italy, 89125 Contact: Caterina Stelitano, MD 0039 0965397653 cstelit@libero.it Principal Investigator: Caterina Stelitano, MD IRCCS Arcispedale "Santa Maria Nuova" Not yet recruiting Reggio Emilia, RE, Italy, 42123 Contact: Francesco Merli, MD 0039 0522296618 merli.francesco@asmn.re.it Principal Investigator: Francesco Merli, MD Università di Roma "La Sapienza" Active, not recruiting Roma, RM, Italy, 00161 Università Cattolica del Sacro Cuore - Policlinico "A. Gemelli" Not yet recruiting Roma, RM, Italy, 00168 Contact: Stefan Hohaus, MD 0039 0630154278 stephan.hohaus@rm.unicatt.it Principal Investigator: Stefan Hohaus, MD Ospedale degli Infermi Not yet recruiting Rimini, RN, Italy, 47900 Contact: Annalia Molinari, MD 0039 0541705423 annalia.molinari@auslrn.net Principal Investigator: Annalia Molinari, MD AO Città della Salute e della Scienza - Ematologia 1U Not yet recruiting Torino, TO, Italy, 10126 Contact: Federica Cavallo, MD 0039 0116334198 f.cavallo@unito.it Principal Investigator: Federica Cavallo, MD AO Città della Salute e della Scienza - SC Ematologia Recruiting Torino, TO, Italy, 10126 Contact: Annalisa Chiappella, MD 0039 0116336751 achiappella@cittadellasalute.to.it Principal Investigator: Annalisa Chiappella, MD AOU "Santa Maria della Misericordia" Recruiting Udine, UD, Italy, 33100 Contact: Francesco Zaja, MD 0039 0432559604 zaja.francesco@aoud.sanita.fgv.it Principal Investigator: Francesco Zaja, MD Ospedale Borgo Roma Not yet recruiting Verona, VR, Italy, 37134 Contact: Fabio Benedetti, MD 0039 045 8124647 fabio.benedetti@univr.it Principal Investigator: Fabio Benedetti, MD Azienda Ospedaliero-Universitaria Careggi Not yet recruiting Firenze, Italy, 50134 Contact: Luigi Rigacci, MD 0039 055 7946448 luigi.rigacci@unifi.it Principal Investigator: Luigi Rigacci, MD Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale Recruiting Napoli, Italy, 80131 Contact: Antonio Pinto, MD 0039 0815903381 a.pinto@istitutotumori.na.it Principal Investigator: Antonio Pinto, MD Università del Piemonte Orientale - SCDU Ematologia Recruiting Novara, Italy, 28100 Contact: Gianluca Gaidano, PROF 0039 03213732194 gaidano@med.unipmn.it Principal Investigator: Gianluca Gaidano, MD A.O. di Perugia - Santa Maria della Misericordia Not yet recruiting Perugia, Italy, 06132 Contact: Leonardo Flenghi, MD 0039 075 5784110 flenghi@yahoo.it Principal Investigator: Leonardo Flenghi, MD Ospedale G. Da Saliceto - AUSL di Piacenza Not yet recruiting Piacenza, Italy, 29121 Contact: Annalisa Arcari, MD 0039 0523 303719 a.arcari@ausl.pc.it Principal Investigator: Annalisa Arcari, MD UO Ematologia Ospedale S.Maria delle Croci Recruiting Ravenna, Italy, 48121 Contact: Monica Tani, MD 0039 0544286223 monica.tani@auslromagna.it Principal Investigator: Monica Tani, MD 收起 <<
NCT00042822	Leukemia Lymp... 展开 >>homa Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms 收起 <<	Phase 2	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT00024180	Leukemia Lymp... 展开 >>homa 收起 <<	Phase 1	Completed	-	United States, Ohio ... 展开 >> Arthur G. James Cancer Hospital - Ohio State University Columbus, Ohio, United States, 43210-1240 收起 <<
NCT00114257	Chronic Myeloproliferative Dis... 展开 >>orders Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms 收起 <<	Phase 1	Completed	-	United States, Texas ... 展开 >> M.D. Anderson Cancer Center at University of Texas Houston, Texas, United States, 77030-4009 收起 <<
NCT00077194	Lymphoma	Phase 2	Completed	-	United States, District of Col... 展开 >>umbia Howard University Cancer Center at Howard University Hospital Washington, District of Columbia, United States, 20060 United States, Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231 United States, Michigan Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201-1379 United States, Wisconsin University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin, United States, 53792-5256 收起 <<
NCT00019318	Lymphoma	Phase 1	Completed	-	United States, Maryland ... 展开 >> Medicine Branch Bethesda, Maryland, United States, 20892 收起 <<
NCT00106613	Carcinoma, Renal Cell ... 展开 >> Neoplasm Metastasis 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> City of Hope National Medical Center Duarte, California, United States, 91010 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98109-1023 收起 <<
NCT00007345	Cutaneous T Cell Lymphoma ... 展开 >> Peripheral T Cell Lymphoma 收起 <<	Phase 2	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic Scottsdale Scottsdale, Arizona, United States, 85259 United States, Arkansas University of Arkansas Little Rock, Arkansas, United States, 72205 United States, California City of Hope National Cancer Center Duarte, California, United States, 91010 Mercy General Hospital Sacramento, California, United States, 95819 United States, District of Columbia Georgetown University Washington, District of Columbia, United States, 20007-2197 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Maryland National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 United States, New York North Shore University Hospital Manhasset, New York, United States, 11030 United States, Pennsylvania University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15261 United States, West Virginia West Virginia University Morgantown, West Virginia, United States, 26506 Australia Royal Adelaide Hospital Adelaide, Australia Peter MacCallum Cancer Centre Melbourne, Australia Sir Charles Gairdner Hospital Perth, Australia 收起 <<
NCT00066638	DS Stage II Plasma Cell Myelom... 展开 >>a DS Stage III Plasma Cell Myeloma Refractory Plasma Cell Myeloma 收起 <<	Phase 2	Completed	-	United States, New York ... 展开 >> Montefiore Medical Center - Moses Campus Bronx, New York, United States, 10467-2490 收起 <<
NCT00077337	Colorectal Cancer	Phase 2	Completed	-	-
NCT00431990	Multiple Myeloma	Phase 1 Phase 2	Unknown	January 2012	Australia, Victoria ... 展开 >> Peter MacCallum Cancer Centre Recruiting Melbourne, Victoria, Australia, 8006 Sub-Investigator: Alvin Milner 收起 <<
NCT00053963	Blastic Phase Chronic Myelogen... 展开 >>ous Leukemia Childhood Central Nervous System Germ Cell Tumor Childhood Choroid Plexus Tumor Childhood Chronic Myelogenous Leukemia Childhood Craniopharyngioma Childhood Grade I Meningioma Childhood Grade II Meningioma Childhood Grade III Meningioma Childhood High-grade Cerebral Astrocytoma Childhood Infratentorial Ependymoma Childhood Low-grade Cerebral Astrocytoma Childhood Spinal Cord Neoplasm Childhood Supratentorial Ependymoma Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Recurrent Childhood Brain Stem Glioma Recurrent Childhood Cerebellar Astrocytoma Recurrent Childhood Cerebral Astrocytoma Recurrent Childhood Ependymoma Recurrent Childhood Medulloblastoma Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor Recurrent Childhood Visual Pathway and Hypothalamic Glioma Refractory Chronic Lymphocytic Leukemia Relapsing Chronic Myelogenous Leukemia Unspecified Childhood Solid Tumor, Protocol Specific 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> Children's Oncology Group Arcadia, California, United States, 91006-3776 收起 <<
NCT01742793	Hodgkin's Lymphoma ... 展开 >> Mature T-cell Lymphoma Multiple Myeloma 收起 <<	Phase 1 Phase 2	Terminated	-	United States, Connecticut ... 展开 >> Yale Cancer Center New Haven, Connecticut, United States, 06519 收起 <<
NCT00383565	Recurrent Adult Diffuse Large ... 展开 >>Cell Lymphoma Recurrent Mantle Cell Lymphoma 收起 <<	Phase 2	Terminated	-	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT03041012	Hiv	Phase 2	Recruiting	August 20, 2019	Denmark ... 展开 >> Department of Infectious Diseases Recruiting Aalborg, Denmark Contact: Henrik Nielsen Dept. of Infectious Diseases, Aarhus University Hospital Recruiting Aarhus, Denmark, 8200 Contact: Jesper D Gunst, MD +45 78452844 jesdam@rm.dk Department of Infectious Diseases Recruiting Hvidovre, Denmark Contact: Thomas Benfield Department of Infectious Diseases Recruiting København, Denmark Contact: Jan Gerstoft Department of Infectious Diseases Recruiting Odense, Denmark Contact: Isik S. Johansen United Kingdom Imperial College Healthcare NHS Trust Recruiting London, United Kingdom Contact: Amin Aamshah Principal Investigator: Sarah Fidler 收起 <<
NCT00007345	-		Completed	-	-
NCT02061449	Cutaneous T-cell Lymphoma	Phase 1	Active, not recruiting	March 2019	United States, New York ... 展开 >> NYU Cancer Institute New York, New York, United States, 10016 收起 <<
NCT00383565	-		Terminated	-	-
NCT00087295	Bladder Cancer ... 展开 >> Transitional Cell Cancer of the Renal Pelvis and Ureter Urethral Cancer 收起 <<	Phase 2	Terminated(Permanently Closed ... 展开 >>Due to Poor Accrual) 收起 <<	-	-
NCT00106301	Carcinoma, Renal Cell ... 展开 >> Prostatic Neoplasms 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> City of Hope National Medical Center Duarte, California, United States, 91010-3000 United States, Florida University of Florida Gainesville, Florida, United States, 32610 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637-1470 United States, Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98109 United Kingdom Royal Marsden Hospital Sutton, United Kingdom, SM2 5PT 收起 <<
NCT00048334	Neoplasms	Phase 1	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT02181218	Lymphoma, T-Cell, Cutaneous ... 展开 >> Lymphoma, T-Cell, Peripheral Hodgkin Disease Lymphoma, Large B-Cell, Diffuse 收起 <<	Phase 1	Recruiting	June 30, 2020	United States, California ... 展开 >> University of California - San Francisco Not yet recruiting San Francisco, California, United States, 94143 Contact: Weiyun Ai, M.D., Ph.D. 415-353-4061 weiai@medicine.ucsf.edu Principal Investigator: Weiyun Ai, M.D., Ph.D. United States, Illinois University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Peter Riedell, M.D. 773-753-3288 Principal Investigator: Peter Riedell, M.D. Sub-Investigator: Justin Kline, M.D. Sub-Investigator: Sonali Smith, M.D. Sub-Investigator: Kenneth Cohen, M.D. Sub-Investigator: Michael Bishop, M.D. United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Neha Mehta-Shah, M.D. 314-747-7402 mehta-n@wustl.edu Principal Investigator: Neha Mehta-Shah, M.D. Sub-Investigator: Nancy Bartlett, M.D. Sub-Investigator: Todd Fehniger, M.D., Ph.D. Sub-Investigator: Amanda Cashen, M.D. Sub-Investigator: Brad Kahl, M.D. Sub-Investigator: Peter Riedell, M.D. 收起 <<
NCT00098527	Adenocarcinoma of the Esophagu... 展开 >>s Adenocarcinoma of the Stomach Recurrent Esophageal Cancer Recurrent Gastric Cancer 收起 <<	Phase 2	Terminated	-	United States, North Carolina ... 展开 >> Duke University Medical Center Durham, North Carolina, United States, 27710 收起 <<
NCT00098397	Male Breast Cancer ... 展开 >> Recurrent Breast Cancer Stage IV Breast Cancer 收起 <<	Phase 2	Completed	-	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02092116	HIV I Infection	Phase 1 Phase 2	Completed	-	Denmark ... 展开 >> Aarhus University Hospital, Skejby Sygehus Aarhus N, Denmark, 8200 收起 <<
NCT00106418	Prostate Cancer ... 展开 >> Metastases 收起 <<	Phase 2	Completed	-	-
NCT01590732	Mycosis Fungoides ... 展开 >> Recurrent Anaplastic Large Cell Lymphoma Recurrent Angioimmunoblastic T-Cell Lymphoma Recurrent Enteropathy-Associated T-Cell Lymphoma Recurrent Hepatosplenic T-Cell Lymphoma Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified Refractory Anaplastic Large Cell Lymphoma Refractory Angioimmunoblastic T-Cell Lymphoma Refractory Enteropathy-Associated T-Cell Lymphoma Refractory Hepatosplenic T-Cell Lymphoma Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified 收起 <<	Phase 1	Completed	-	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02092116	-		Completed	-	-
NCT02783625	Lymphoma Rela... 展开 >>psed/Refractory T-cell Lymphomas 收起 <<	Phase 1	Recruiting	May 2019	United States, California ... 展开 >> Stanford University Medical Center Recruiting Stanford, California, United States, 94305-5408 Contact: Youn Kim, MD 650-498-6000 United States, Massachusetts Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: Eric Jacobsen, MD 617-582-9086 United States, Missouri University of Washington School of Medicine in St. Louis Recruiting Saint Louis, Missouri, United States, 63110 Contact: Neha Mehta-Shah, MD 314-362-5654 Principal Investigator: Neha Mehta-Shah, MD Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Neha Mehta-Shah, MD 314-362-5654 Principal Investigator: Neha Mehta-Shah, MD United States, New Jersey Memoral Sloan Kettering Cancer Center Basking Ridge Recruiting Basking Ridge, New Jersey, United States Contact: Steven Horwitz, MD 212-639-3045 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Steven Horwitz, MD 212-639-3045 United States, New York Memorial Sloan Kettering Cancer Center @ Commack Recruiting Commack, New York, United States, 11725 Contact: Steven Horwitz, MD 212-639-3045 Memoral Sloan Kettering Westchester Recruiting Harrison, New York, United States Contact: Steven Horwitz, MD 212-639-3045 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Steven Horwitz, MD 212-639-3045 Contact: Alison Moskowitz, MD 212-639-4839 Principal Investigator: Steven Horwitz, MD Memorial Sloan Kettering at Mercy Medical Center Recruiting Rockville Centre, New York, United States Contact: Steven Horwitz, MD 212-639-3045 收起 <<
NCT00098813	-		Completed	-	-
NCT00084682	-		Completed	-	-
NCT00062075	Adult Acute Myeloid Leukemia W... 展开 >>ith 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Promyelocytic Leukemia (M3) Recurrent Adult Acute Myeloid Leukemia 收起 <<	Phase 2	Completed	-	United States, Illinois ... 展开 >> University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637-1470 United States, Tennessee Vanderbilt University Nashville, Tennessee, United States, 37232 收起 <<
NCT00098813	Recurrent Thyroid Cancer ... 展开 >> Stage IV Follicular Thyroid Cancer Stage IV Papillary Thyroid Cancer 收起 <<	Phase 2	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center at Suffolk Commack, New York, United States, 11725 收起 <<
NCT00086827	Recurrent Small Cell Lung Canc... 展开 >>er 收起 <<	Phase 2	Completed	-	United States, Ohio ... 展开 >> Ohio State University Columbus, Ohio, United States, 43210 收起 <<
NCT00106431	Cutaneous T-cell Lymphoma	Phase 2	Completed	-	United States, California ... 展开 >> UCLA Jonsson Cancer Center Los Angeles, California, United States, 90095 Stanford Comprehensive Cancer Center Stanford, California, United States, 94305 United States, Massachusetts Boston Medical Center Boston, Massachusetts, United States, 02118 United States, Pennsylvania University of Pennsylvania Abrahamson Cancer Center Philadelphia, Pennsylvania, United States, 19104 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 France Research Site Various Cities, France Germany Research Site Various Cities, Germany Poland Research Site Various Cities, Poland Russian Federation Research Site Various Cities, Russian Federation United Kingdom Research Site Various Cities, United Kingdom 收起 <<
NCT00084682	Stage IV Squamous Cell Carcino... 展开 >>ma of the Hypopharynx Stage IV Squamous Cell Carcinoma of the Larynx Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IV Squamous Cell Carcinoma of the Oropharynx 收起 <<	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467-2490 收起 <<
NCT00106431	-		Completed	-	-
NCT01280526	Peripheral T Cell Lymphoma	Phase 1 Phase 2	Completed	-	France ... 展开 >> Hôpital Henri Mondor Créteil, France, 94010 CHU de Dijon Dijon, France, 21000 Hôpital Claude Huriez Lille, France, 59037 Centre Léon Bérard Lyon cedex 8, France, 69373 Hôpital St Louis Paris, France, 75475 Centre Hospitalier Lyon Sud Pierre-Bénite, France, 69495 Centre Henri Becquerel Rouen, France, 76038 Institut Gustave Roussy Villejuif, France, 94805 收起 <<
NCT00084461	Gastrinoma Gl... 展开 >>ucagonoma Insulinoma Metastatic Gastrointestinal Carcinoid Tumor Pancreatic Polypeptide Tumor Pulmonary Carcinoid Tumor Recurrent Gastrointestinal Carcinoid Tumor Recurrent Islet Cell Carcinoma Regional Gastrointestinal Carcinoid Tumor Somatostatinoma 收起 <<	Phase 2	Terminated	-	United States, Ohio ... 展开 >> Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT03161223	Lymphoma, T-Cell	Phase 1 Phase 2	Recruiting	June 30, 2020	United States, New York ... 展开 >> Center for Lymphoid Malignancies at CUMC Recruiting New York, New York, United States, 10019 Contact: Michelle Malanga, MPA Principal Investigator: Owen A O'Connor, M.D., PhD Sub-Investigator: Jennifer E Amengual, M.D. Sub-Investigator: Ahmed Sawas, M.D. Sub-Investigator: Changchun Deng, M.D. Sub-Investigator: Lorenzo Falchi, M.D. Italy University of Bologna Not yet recruiting Bologna, Italy Principal Investigator: Pier Luigi Zinzani, M.D., PhD. Korea, Republic of Samsung Medical Center Not yet recruiting Seoul, Korea, Republic of Principal Investigator: Won Seog Kim, M.D., Ph.D. 收起 <<
NCT00091195	Primary Peritoneal Cavity Canc... 展开 >>er Recurrent Ovarian Epithelial Cancer 收起 <<	Phase 2	Terminated(Administratively co... 展开 >>mplete.) 收起 <<	-	United States, North Carolina ... 展开 >> High Point Regional Hospital High Point, North Carolina, United States, 27261 Wake Forest University Health Sciences Winston-Salem, North Carolina, United States, 27157 收起 <<
NCT01302808	Lung Cancer M... 展开 >>etastatic Cancer 收起 <<	Phase 1 Phase 2	Completed	-	United States, Texas ... 展开 >> Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas Dallas, Texas, United States, 75390 收起 <<
NCT00085527	Ovarian Cancer	Phase 2	Withdrawn	-	United States, Illinois ... 展开 >> Cardinal Bernardin Cancer Center at Loyola University Medical Center Maywood, Illinois, United States, 60153 收起 <<
NCT00104884	Malignant Melanoma ... 展开 >> Melanoma 收起 <<	Phase 2	Terminated(The study was termi... 展开 >>nated on May 17, 2006 due to slow accrual.) 收起 <<	-	-
NCT01933594	HIV Infections	Phase 1 Phase 2	Completed	-	United States, Alabama ... 展开 >> Alabama CRS Birmingham, Alabama, United States, 35294 United States, California UCLA CARE Center CRS Los Angeles, California, United States, 90035 United States, Colorado University of Colorado Hospital CRS Aurora, Colorado, United States, 80045 United States, Massachusetts Massachusetts General Hospital CRS (MGH CRS) Boston, Massachusetts, United States, 02114 United States, New York University of Rochester Adult HIV Therapeutic Strategies Network CRS Rochester, New York, United States, 14642 United States, North Carolina Chapel Hill CRS Chapel Hill, North Carolina, United States, 27599 United States, Ohio Ohio State University CRS Columbus, Ohio, United States, 43210 United States, Pennsylvania Penn Therapeutics, CRS Philadelphia, Pennsylvania, United States, 19104 University of Pittsburgh CRS Pittsburgh, Pennsylvania, United States, 15213 United States, Washington University of Washington AIDS CRS Seattle, Washington, United States, 98104-9929 收起 <<
NCT00379639	-		Completed	-	-
NCT00112463	-		Completed	-	-
NCT00104884	-		Terminated(The study was termi... 展开 >>nated on May 17, 2006 due to slow accrual.) 收起 <<	-	-
NCT02281279	B-cell Adult Acute Lymphoblast... 展开 >>ic Leukemia Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Intraocular Lymphoma Nodal Marginal Zone B-cell Lymphoma Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Immunoblastic Large Cell Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory Hairy Cell Leukemia Small Intestine Lymphoma Splenic Marginal Zone Lymphoma Testicular Lymphoma Waldenström Macroglobulinemia 收起 <<	Phase 1 Phase 2	Withdrawn	-	-
NCT02341014	T-cell Lymphomas ... 展开 >> Relapsed or Refractory 收起 <<	Phase 1 Phase 2	Active, not recruiting	January 2019	United States, Nebraska ... 展开 >> University of Nebraska Medical Center Omaha, Nebraska, United States, 68198-7680 United States, New Jersey Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States, 07920 United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan Kettering Westchester Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan Kettering at Mercy Medical Center Rockville Centre, New York, United States, 11570 收起 <<
NCT00112463	Adult Alveolar Soft-part Sarco... 展开 >>ma Adult Angiosarcoma Adult Epithelioid Sarcoma Adult Extraskeletal Chondrosarcoma Adult Extraskeletal Osteosarcoma Adult Fibrosarcoma Adult Leiomyosarcoma Adult Liposarcoma Adult Malignant Fibrous Histiocytoma Adult Malignant Hemangiopericytoma Adult Malignant Mesenchymoma Adult Neurofibrosarcoma Adult Rhabdomyosarcoma Adult Synovial Sarcoma Gastrointestinal Stromal Tumor Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Recurrent Adult Soft Tissue Sarcoma Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Stage III Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma 收起 <<	Phase 2	Completed	-	-
NCT00085540	Adult Anaplastic Astrocytoma ... 展开 >> Adult Anaplastic Oligodendroglioma Adult Giant Cell Glioblastoma Adult Gliosarcoma Recurrent Adult Brain Tumor 收起 <<	Phase 1 Phase 2	Completed	-	United States, California ... 展开 >> University of California Los Angeles Los Angeles, California, United States, 90095 University of California San Francisco San Francisco, California, United States, 94143 United States, Maryland National Cancer Institute Neuro-Oncology Branch Bethesda, Maryland, United States, 20814 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 United States, Pennsylvania University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15232 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Wisconsin University of Wisconsin Madison, Wisconsin, United States, 53792 收起 <<
NCT03742921	-		Not yet recruiting	April 17, 2023	-
NCT00379639	Pancreatic Cancer	Phase 1	Completed	-	United States, Tennessee ... 展开 >> Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 收起 <<
NCT00085540	-		Completed	-	-
NCT01902225	Lymphoma T-Ce... 展开 >>ll Lymphoma Cutaneous Lymphoma 收起 <<	Phase 1	Recruiting	April 2019	United States, California ... 展开 >> UCSF Helen Diller Family Comprehensive Cancer Center Recruiting San Francisco, California, United States, 94115 Contact: Weiyun Ai, MD, PHD 415-353-4061 weiyun.ai@ucsf.edu Principal Investigator: Weiyun Ai, MD, PhD United States, Ohio Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Jonathan Branmmer, MD 614-293-2268 Jonathan.Brammer@osumc.edu 收起 <<
NCT01897012	MYC Positive ... 展开 >>Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Burkitt Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Recurrent Hodgkin Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Refractory Burkitt Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Follicular Lymphoma Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Refractory Hodgkin Lymphoma Refractory Mantle Cell Lymphoma Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma 收起 <<	Phase 1	Active, not recruiting	-	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00963274	Leukemia Lymp... 展开 >>homa 收起 <<	Phase 1	Completed	-	United States, Illinois ... 展开 >> Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago, Illinois, United States, 60611 United States, Maryland University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 United States, North Carolina University of North Carolina Chapel Hill, North Carolina, United States, 27599 United States, Tennessee Vanderbilt-Ingram Cancer Center, Vanderbilt University Nashville, Tennessee, United States, 37232 United States, Virginia Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 收起 <<
NCT01908777	T Cell Non-Hodgkin Lymphoma	Phase 2	Recruiting	July 2020	United States, Florida ... 展开 >> Moffitt Cancer Center Recruiting Tampa, Florida, United States, 33612 Contact: Farhad Khimani, MD Contact 1-888-663-3488 Principal Investigator: Farhad Khimani, MD United States, New Jersey Memoral Sloan Kettering Cancer Center Recruiting Basking Ridge, New Jersey, United States Contact: Steven Horwitz, MD 212-639-3045 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Steve Horwitz, MD 212-639-3045 United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Recruiting Commack, New York, United States, 11725 Contact: Steven Horwitz, MD 212-639-3045 Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Steven Horwitz, MD 212-639-3045 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 11065 Contact: Steven Horwitz, MD 212-639-3045 Contact: Parastoo Dahi, MD 212-639-5846 Principal Investigator: Steven Horwitz, MD Weill Cornell Medical Center Recruiting New York, New York, United States Contact: Jia Ruan, MD Principal Investigator: Jia Ruan, MD Memorial Sloan Kettering at Mercy Medical Center Recruiting Rockville Centre, New York, United States Contact: Steven Horwitz, MD United States, Washington University of Washington School of Medicine Recruiting Seattle, Washington, United States, 98109 Contact: Andrei Shustov, MD Principal Investigator: Andrei Shustov, MD 收起 <<
NCT01796002	Peripheral T-cell Lymphoma	Phase 3	Active, not recruiting	July 2024	-
NCT02232516	Adult Nasal Type Extranodal NK... 展开 >>/T-cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Hepatosplenic T-cell Lymphoma Peripheral T-cell Lymphoma Stage I Cutaneous T-cell Non-Hodgkin Lymphoma Stage IA Mycosis Fungoides/Sezary Syndrome Stage IB Mycosis Fungoides/Sezary Syndrome Stage II Cutaneous T-cell Non-Hodgkin Lymphoma Stage IIA Mycosis Fungoides/Sezary Syndrome Stage IIB Mycosis Fungoides/Sezary Syndrome Stage III Cutaneous T-cell Non-Hodgkin Lymphoma Stage IIIA Mycosis Fungoides/Sezary Syndrome Stage IIIB Mycosis Fungoides/Sezary Syndrome Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma Stage IVA Mycosis Fungoides/Sezary Syndrome Stage IVB Mycosis Fungoides/Sezary Syndrome 收起 <<	Phase 2	Recruiting	August 2020	United States, California ... 展开 >> City of Hope Recruiting Duarte, California, United States, 91010 Contact: Jasmine Zain, MD 626-256-4673 Principal Investigator: Jasmine Zain, MD United States, Connecticut Yale University Not yet recruiting New Haven, Connecticut, United States, 06520 Contact: Francine M. Foss, MD 203-200-4363 Principal Investigator: Francine M. Foss, MD United States, Illinois Northwestern University Recruiting Chicago, Illinois, United States, 60611 Contact: Adam M. Petrich, MD 312-695-4537 Principal Investigator: Adam M. Petrich, MD United States, New York Weill Cornell Medicine Recruiting New York, New York, United States, 10021 Contact: Jia Ruan, MD 646-962-2064 Principal Investigator: Jia Ruan, MD United States, Washington Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Not yet recruiting Seattle, Washington, United States, 98109 Contact: Andrei R. Shustov 206-288-6739 Principal Investigator: Andrei R. Shustov, MD 收起 <<
NCT02616874	HIV	Phase 1	Completed	-	Spain ... 展开 >> Germans Trias i Pujol Hospital Badalona, Barcelona, Spain, 08916 Clinic Hospital Barcelona, Spain, 08036 收起 <<
NCT02616965	Cutaneous T-cell Lymphoma (CTC... 展开 >>L) 收起 <<	Phase 1	Recruiting	July 2021	United States, Pennsylvania ... 展开 >> Fox Chase Cancer Center Recruiting Philadelphia, Pennsylvania, United States, 19111 Contact: Stefan K. Barta, MD 215-728-2674 Principal Investigator: Stefan K. Barta, MD 收起 <<
NCT01947140	Lymphoid Malignancies ... 展开 >> Multiple Myeloma Lymphoma Hodgkin Lymphoma Non-hodgkin Lymphoma 收起 <<	Phase 1 Phase 2	Recruiting	December 2018	United States, New York ... 展开 >> Columbia University Medical Center Recruiting New York, New York, United States, 10019 Contact: Renee Lichtenstein 212-326-5720 rl2619@cumc.columbia.edu Principal Investigator: Jennifer E Amengual, MD 收起 <<
NCT01456039	Lymphoma, T-cell, Peripheral	Phase 1 Phase 2	Active, not recruiting	June 30, 2018	Japan ... 展开 >> Nagoya Daini Red Cross Hospital Nagoya, Aichi, Japan, 466-8650 Nagoya City University Hospital Nagoya, Aichi, Japan, 467-8602 National Cancer Center Hospital East Kashiwa, Chiba, Japan, 277-8577: Ehime University Hospital To-on, Ehime, Japan, 791-0295 Chugoku Central Hospital Fukuyamashi, Hiroshima, Japan, 720-0001 Sapporo Hokuyu Hospital Sapporo, Hokkaido, Japan, 003-0006 Sapporo Medical University Hospital Sapporo, Hokkaido, Japan, 060-8543 Tokai University School of Medicine Isehara, Kanagawa, Japan, 259-1193 Kochi Medical School Hospital Nankoku, Kochi, Japan, 783-8505 Kinki University Hospital Sayama, Osaka, Japan, 589-8511 National Cancer Center Hospital Chuo, Tokyo, Japan, 104-0045 Japanese Red Cross Medical Center Shibuya, Tokyo, Japan, 150-8935 Kyushu University Hospital Fukuoka, Japan, 812-8582 Kumamoto University Hospital Kumamoto, Japan, 860-8556 University hospital, Kyoto prefectural University of Medicine Kyoto, Japan, 602-8566 Tohoku University Hospital Miyagi, Japan, 980-8574 The Cancer Institute Hospital of JFCR Tokyo, Japan, 135-8550 收起 <<
NCT02757248	PTCL CTCL	Phase 1	Withdrawn(Boehringer Ingelheim... 展开 >> is discontinuing their volasertib development program) 收起 <<	-	-
NCT01456039	-		Active, not recruiting	-	-
NCT01998035	Lymphoid Malignancies ... 展开 >> Lymphoma Hodgkin Lymphoma Non-hodgkin Lymphoma 收起 <<	Phase 1 Phase 2	Recruiting	February 2019	United States, New York ... 展开 >> Columbia University Medical Center Recruiting New York, New York, United States, 10019 Contact: Celeste Rojas 212-326-5720 cr2393@cumc.columbia.edu Principal Investigator: Owen A O'Connor, MD, Ph.D. 收起 <<
NCT01445340	Mycosis Fungoides ... 展开 >> Cutaneous T-Cell Lymphoma Neoplasms 收起 <<	Phase 1	Terminated	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT00765102	-		Terminated(There was a change ... 展开 >>in the Sponsor's research strategy; safety concerns were not a factor.) 收起 <<	-	-
NCT02393794	Triple-Negative Breast Cancer ... 展开 >> Breast Cancer 收起 <<	Phase 1 Phase 2	Recruiting	July 2020	United States, Kansas ... 展开 >> University of Kansas Cancer Center - Clinical Research Center Recruiting Fairway, Kansas, United States, 66205 Contact: Priyanka Sharma, MD 913-588-6029 psharma2@kumc.edu Contact: Clinical Trials Nurse Navigator 913-945-7552 ctnursenav@kumc.edu University of Kansas Cancer Center - West Recruiting Kansas City, Kansas, United States, 66112 Contact: Clinical Trials Nurse Navigator 913-945-7552 ctnursenav@kumc.edu University of Kansas Cancer Center - Overland Park Recruiting Overland Park, Kansas, United States, 66210 Contact: Clinical Trials Nurse Navigator 913-945-7552 ctnursenav@kumc.edu University of Kansas Cancer Center - Westwood Recruiting Westwood, Kansas, United States, 66205 Contact: Clinical Trials Nurse Navigator 913-945-7552 ctnursenav@kumc.edu United States, Missouri University of Kansas Cancer Center - South Recruiting Kansas City, Missouri, United States, 64131 Contact: Clinical Trials Nurse Navigator 913-945-7552 ctnursenav@kumc.edu University of Kansas Cancer Center - North Recruiting Kansas City, Missouri, United States, 64154 Contact: Clinical Trials Nurse Navigator 913-945-7552 ctnursenav@kumc.edu University of Kansas Cancer Center - Lee's Summit Recruiting Lee's Summit, Missouri, United States, 64064 Contact: Clinical Trials Nurse Navigator 913-945-7552 ctnursenav@kumc.edu 收起 <<
NCT00426764	-		Active, not recruiting	-	-
NCT00765102	Multiple Myeloma	Phase 2	Terminated(There was a change ... 展开 >>in the Sponsor's research strategy; safety concerns were not a factor.) 收起 <<	-	United States, California ... 展开 >> Loma Linda University Cancer Center Loma Linda, California, United States, 92354 Desert Cancer Care, Inc Rancho Mirage, California, United States, 92270 Santa Barbara Hematology Oncology Medical Group, Inc. Santa Barbara, California, United States, 93105 James R Berenson, MD, Inc. West Hollywood, California, United States, 90069 United States, Georgia Georgia Cancer Specialists I, PC Atlanta, Georgia, United States, 30341 United States, Maryland Center for Cancer and Blood Disorders Bethesda, Maryland, United States, 20817 United States, North Carolina Mecklenburg Medical Group Charlotte, North Carolina, United States, 28204 United States, Texas Baylor Sammons Cancer Center Dallas, Texas, United States, 75246 Dallas Oncology Consultants, P.A. Duncanville, Texas, United States, 75137 Oncology Consultants, P.A Houston, Texas, United States, 77024 United States, Utah Central Utah Clinic, PC Provo, Utah, United States, 84604 United States, Washington Virginia Mason Medical Centre Seattle, Washington, United States, 98101 收起 <<
NCT01846390	Peripheral T-Cell Lymphoma ... 展开 >> Diffuse Large B-Cell Lymphoma 收起 <<	Phase 1	Completed	-	Canada, Alberta ... 展开 >> Tom Baker Cancer Centre Calgary, Alberta, Canada, T2N 4N2 Canada, British Columbia BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, New Brunswick Regional Health Authority B, Zone 2 Saint John, New Brunswick, Canada, E2L 4L2 Canada, Nova Scotia QEII Health Sciences Centre Halifax, Nova Scotia, Canada, B3H 1V7 Canada, Ontario Odette Cancer Centre Toronto, Ontario, Canada, M4N 3M5 Univ. Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT01755975	Multiple Myeloma ... 展开 >> Non-Hodgkin's Lymphoma 收起 <<	Phase 1 Phase 2	Active, not recruiting	December 2019	United States, Connecticut ... 展开 >> Saint Francis/Mount Sinai Regional Cancer Center Hartford, Connecticut, United States, 06105 United States, Nebraska University of Nebraska Medical Center Omaha, Nebraska, United States, 68198-7680 United States, New Jersey Memorial Sloan Kettering at Basking Ridge Basking Ridge, New Jersey, United States, 07920 United States, New York Memorial Sloan Kettering Cancer Center at Commack Commack, New York, United States, 11725 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Weill Cornell Medical Center New York, New York, United States Memorial Sloan Kettering Cancer Center at Mercy Rockville Centre, New York, United States, 11570 收起 <<
NCT00426764	Peripheral T-cell Lymphoma	Phase 2	Active, not recruiting	May 17, 2018	-
NCT01324323	-		Completed	-	-
NCT01979276	Multiple Myeloma	Phase 1 Phase 2	Terminated(this study was term... 展开 >>inated due to losing financial support, and enrollment challenges) 收起 <<	-	United States, New York ... 展开 >> Weill Cornell Medical College New York, New York, United States, 10065 收起 <<
NCT03141203	Peripheral T Cell Lymphoma	Phase 1 Phase 2	Recruiting	February 2021	United Kingdom ... 展开 >> Queen Elizabeth Hospital Recruiting Birmingham, United Kingdom Principal Investigator: Ram Malladi St James's University Hospital Recruiting Leeds, United Kingdom Principal Investigator: Rod Johnson Leicester Royal Infirmary Recruiting Leicester, United Kingdom Principal Investigator: Simon Wagner Clatterbridge Cancer Centre Recruiting Liverpool, United Kingdom Principal Investigator: Nagesh Kalakonda Guy's Hospital Recruiting London, United Kingdom Principal Investigator: Paul Fields St Bartholomew's Hospital Recruiting London, United Kingdom Principal Investigator: Jeff Davies University College London Hospitals Recruiting London, United Kingdom Principal Investigator: Kate Cwynarski Christie Hospital Recruiting Manchester, United Kingdom Principal Investigator: Kim Linton Nottingham University Hospitals Recruiting Nottingham, United Kingdom Principal Investigator: Chris Fox Churchill Hospital Recruiting Oxford, United Kingdom Principal Investigator: Graham Collins Derriford Hospital Recruiting Plymouth, United Kingdom Principal Investigator: David Lewis Southampton General Hospital Recruiting Southampton, United Kingdom Principal Investigator: Andrew Davies The Royal Marsden NHS Foundation Trust Recruiting Sutton, United Kingdom, SM2 5PT Principal Investigator: Dima El-Sharkawi 收起 <<
NCT01324323	Hematologic Malignancy ... 展开 >> Malignant Lymphoma 收起 <<	Phase 1	Completed	-	United States, Florida ... 展开 >> Florida Cancer Specialists Sarasota, Florida, United States, 34232 United States, Tennessee Sarah Canon Research Institute Nashville, Tennessee, United States, 37203 United Kingdom Sarah Cannon Research UK London, United Kingdom, W1G6AD 收起 <<
NCT01938833	-		Terminated(Closed by Sponsor)	-	-
NCT02203578	Graft Versus Host Disease	Not Applicable	Terminated(slow accrual)	-	United States, New Jersey ... 展开 >> Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 收起 <<
NCT01938833	HER2-negative Breast Cancer ... 展开 >> Inflammatory Breast Cancer Male Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer 收起 <<	Phase 1 Phase 2	Terminated(Closed by Sponsor)	-	United States, Pennsylvania ... 展开 >> Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 收起 <<
NCT02850016	Human Immunodeficiency Virus (... 展开 >>HIV) 收起 <<	Phase 2	Recruiting	December 2019	United States, New York ... 展开 >> The Rockefeller University Recruiting New York, New York, United States, 10065 Contact: Katelyn Bastert 800-782-2737 rucares@rockefeller.edu Principal Investigator: Marina Caskey, MD Denmark Aarhus University Hospital Recruiting Aarhus, Denmark Contact: Ole Sogaard, MD, PhD +45 7845 2842 olesoega@rm.dk Principal Investigator: Ole Sogaard, MD, PhD Germany University of Cologne Recruiting Cologne, Germany, 50937 Contact: Gisela Kremer, RN +41-221-478-3324 gisela.kremer@uk-koeln.de Principal Investigator: Gerd Kaetkenheuer, MD 收起 <<
NCT01353664	Lymphoma Canc... 展开 >>er 收起 <<	Phase 2	Completed	-	United States, Florida ... 展开 >> Florida Cancer Specialists Sarasota, Florida, United States, 34232 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United Kingdom Sarah Cannon Research UK London, United Kingdom, W1G6AD 收起 <<
NCT02512497	Cutaneous T-cell Lymphoma ... 展开 >> T-Prolymphocytic Leukemia T-Large Granulocytic Leukemia T-Lymphoblastic Leukemia/Lymphoma Peripheral T-Cell Lymphoma 收起 <<	Phase 1	Recruiting	October 2019	United States, Ohio ... 展开 >> The Ohio State University Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Rachel Conley Rachel.Conley@osumc.edu Principal Investigator: Jonathan Brammer, MD 收起 <<
NCT01979276	-		Terminated(this study was term... 展开 >>inated due to losing financial support, and enrollment challenges) 收起 <<	-	-
NCT01353664	-		Completed	-	-
NCT02203578	-		Terminated(slow accrual)	-	-
NCT01324310	Hematologic Malignancy ... 展开 >> Malignant Lymphoma 收起 <<	Phase 1	Completed	-	United States, Florida ... 展开 >> Florida Cancer Specialists Sarasota, Florida, United States, 34232 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United Kingdom Sarah Cannon Research UK London, United Kingdom, W1G6AD 收起 <<
NCT01324310	-		Completed	-	-
NCT01822886	Peripheral T-cell Lymphoma	Phase 2	Completed	-	Italy ... 展开 >> A.O. SS. Antonio e Biagio e C. Arrigo Alessandria, Italy, 15121 Istituto di Ematologia ed Oncologia Medica A. Seragnoli Policlinico S. Orsola Bologna, Italy, 40138 Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Italy, 20133 A.O. Universitaria Citta' Della Salute E Della Scienza Di Torino Torino, Italy, 10126 收起 <<
NCT01913119	Histologically Proven Extranod... 展开 >>al NKTcell Lymphoma 收起 <<	Early Phase 1	Completed	-	Korea, Republic of ... 展开 >> National Cancer Center Goyang-si, Gyeonggi-do, Korea, Republic of, 410-769 Korea Cancer Center Hospital Nowon-gu, Seoul, Korea, Republic of, 139-709 Severance Hospital Seodaemun-gu, Seoul, Korea, Republic of, 120-752 Asan Medical Center Songpa-gu, Seoul, Korea, Republic of, 138-736 收起 <<
NCT01537744	Solid Tumors ... 展开 >>Virally Mediated Cancers and Liposarcoma 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> Sidney Kimmel Cancer Center @ Johns Hopkins Baltimore, Maryland, United States, 21231 收起 <<
NCT01638533	Glioma Lympho... 展开 >>ma Metastatic Malignant Solid Neoplasm Neuroendocrine Neoplasm Recurrent Adult Soft Tissue Sarcoma Recurrent Bladder Carcinoma Recurrent Breast Carcinoma Recurrent Chronic Lymphocytic Leukemia Recurrent Colorectal Carcinoma Recurrent Head and Neck Carcinoma Recurrent Lung Carcinoma Recurrent Malignant Solid Neoplasm Recurrent Melanoma Recurrent Pancreatic Carcinoma Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Recurrent Prostate Carcinoma Recurrent Renal Cell Carcinoma Recurrent Thyroid Gland Carcinoma Refractory Chronic Lymphocytic Leukemia Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Stage III Breast Cancer AJCC v7 Stage III Colorectal Cancer AJCC v7 Stage III Cutaneous Melanoma AJCC v7 Stage III Lung Cancer AJCC v7 Stage III Pancreatic Cancer AJCC v6 and v7 Stage III Prostate Cancer AJCC v7 Stage III Renal Cell Cancer AJCC v7 Stage III Soft Tissue Sarcoma AJCC v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIA Colorectal Cancer AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIB Colorectal Cancer AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Breast Cancer AJCC v7 Stage IIIC Colorectal Cancer AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Breast Cancer AJCC v6 and v7 Stage IV Colorectal Cancer AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Stage IV Lung Cancer AJCC v7 Stage IV Pancreatic Cancer AJCC v6 and v7 Stage IV Prostate Cancer AJCC v7 Stage IV Renal Cell Cancer AJCC v7 Stage IV Soft Tissue Sarcoma AJCC v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7 Unresectable Solid Neoplasm 收起 <<	Phase 1	Recruiting	-	United States, California ... 展开 >> City of Hope Comprehensive Cancer Center Suspended Duarte, California, United States, 91010 University of California Davis Comprehensive Cancer Center Suspended Sacramento, California, United States, 95817 City of Hope South Pasadena Recruiting South Pasadena, California, United States, 91030 Contact: Stephen C. Koehler 626-396-2900 skoehler@cohmg.com Principal Investigator: Stephen C. Koehler United States, Georgia Emory University Hospital/Winship Cancer Institute Suspended Atlanta, Georgia, United States, 30322 United States, Illinois University of Chicago Comprehensive Cancer Center Active, not recruiting Chicago, Illinois, United States, 60637 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Recruiting Baltimore, Maryland, United States, 21287 Contact: Roisin M. Connolly 410-955-8804 jhcccro@jhmi.edu Principal Investigator: Roisin M. Connolly National Cancer Institute Developmental Therapeutics Clinic Suspended Bethesda, Maryland, United States, 20892 National Institutes of Health Clinical Center Active, not recruiting Bethesda, Maryland, United States, 20892 United States, Michigan Wayne State University/Karmanos Cancer Institute Suspended Detroit, Michigan, United States, 48201 United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Paul Haluska 507-284-2511 haluska.paul@mayo.edu Principal Investigator: Paul Haluska United States, Ohio Case Western Reserve University Active, not recruiting Cleveland, Ohio, United States, 44106 United States, Pennsylvania Penn State Milton S Hershey Medical Center Active, not recruiting Hershey, Pennsylvania, United States, 17033-0850 Thomas Jefferson University Hospital Active, not recruiting Philadelphia, Pennsylvania, United States, 19107 United States, Wisconsin University of Wisconsin Hospital and Clinics Recruiting Madison, Wisconsin, United States, 53792 Contact: Roisin M. Connolly 410-614-9217 rconnol2@jhmi.edu Principal Investigator: Roisin M. Connolly Canada, Ontario University Health Network-Princess Margaret Hospital Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Lillian L. Siu 416-946-4501 clinical.trials@uhn.on.ca Principal Investigator: Lillian L. Siu 收起 <<
NCT03278782	Lymphoid Haematopoietic ... 展开 >> Malignant Neoplasms Cutaneous T-Cell Lymphoma Refractory Cutaneous T-cell Lymphoma 收起 <<	Phase 1 Phase 2	Recruiting	November 2020	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Clinical Research Operations spiyer@mdanderson.org 收起 <<
NCT03547700	Lymphoma, T-Cell, Peripheral	Phase 1 Phase 2	Recruiting	July 2021	United States, Michigan ... 展开 >> University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Ryan Wilcox, M.D. 734-615-1482 rwilcox@med.umich.edu Contact: Sumana Devata 734-615-7813 sdevata@med.umich.edu 收起 <<
NCT02296398	-		Completed	-	United States, Illinois ... 展开 >> Northwestern University Dermatology Department Chicago, Illinois, United States, 60611 收起 <<
NCT03355768	Lymphoma, T-Cell, Peripheral	Phase 3	Not yet recruiting	January 2020	United States, New York ... 展开 >> Center for Lymphoid Malignancies at CUMC Not yet recruiting New York, New York, United States, 10019 Contact: Michelle Malanga, MPA 212-326-5731 mm4629@cumc.columbia.edu 收起 <<
NCT01738594	Recurrent Cutaneous T-cell Non... 展开 >>-Hodgkin Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Stage I Cutaneous T-cell Non-Hodgkin Lymphoma Stage IA Mycosis Fungoides/Sezary Syndrome Stage IB Mycosis Fungoides/Sezary Syndrome Stage II Cutaneous T-cell Non-Hodgkin Lymphoma Stage IIA Mycosis Fungoides/Sezary Syndrome Stage IIB Mycosis Fungoides/Sezary Syndrome Stage III Cutaneous T-cell Non-Hodgkin Lymphoma Stage IIIA Mycosis Fungoides/Sezary Syndrome Stage IIIB Mycosis Fungoides/Sezary Syndrome Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma Stage IVA Mycosis Fungoides/Sezary Syndrome Stage IVB Mycosis Fungoides/Sezary Syndrome 收起 <<	Phase 1	Active, not recruiting	January 2020	United States, Illinois ... 展开 >> Northwestern University Chicago, Illinois, United States, 60611 收起 <<
NCT03770000	T Cell Lymphoma	Phase 1 Phase 2	Not yet recruiting	November 2020	United States, Texas ... 展开 >> The University of Texas MD Anderson Cancer Center, Not yet recruiting Houston, Texas, United States, 77030 Contact: Swaminathan P Iyer, MD The University of Texas MD Anderson Cancer Center, Not yet recruiting Houston, Texas, United States, 77030 Contact: Auris Huen, MD 收起 <<

靶点	HDAC2 HDAC2, IC50:47 nM HDAC1 HDAC1, IC50:36 nM
描述	The inhibition of class I HDACs increased the acetylation of histone proteins, which affects the tertiary chromatin structure and leads to altered expression of genes involved in cell proliferation, apoptosis, and differentiation. It makes a key role of HDAC inhibition in anti-proliferation of tumor cells. Romidepsin (Istodax, FK228, FR901228, depsipeptide), produced by Chromobacterium violaceum, can inhibit HDAC1 and HDAC2 with IC50 values of 36 nM and 47 nM (measured by HDACs prepared from 293T cell lysate), respectively^[1]. The increase of H4 K5, H4 K12, and H3 K9 acetylation can be observed in mononuclear cells from CLL patients when treated with 0.04 - 0.4 μM romidepsin, with no changes in H4K16 acetylation, H3K14 acetylation or H3K9 methylation. Romidepsin can induce cell death through either apoptosis or cell growth arrest. The induction of apoptosis occurs via TNF receptor pathway in CLL cells treated with 0.00038 - 0.38 μM for 4h^[2]. Also, an additional G1 and G2-arrest, as well as induction of p21 can be observed with absence or presence of P53 when cells treated with romidepsin on concentration of 10 - 100 ng/ml for 24 hours, suggesting that romidepsin can cause p53-independent cell cycle arrest. Consistent with that, PC3 (p53-null) cells treated with 10 ng/ml romidepsin for 12h shows the increased level of p21 and growth arrest, which also indicates the effects of romidepsin on induction of p21 and growth arrest is p53-independent^[3]. Up to now, romidepsin is approved by FDA to the treatment of CTCL and PTCL. It is also in clinical trials as monotherapy or in combination therapy with various anticancer agents in patients with hematologic and solid malignancies, such as pancreatic, breast, non-small cell lung cancer, and thyroid cancers^[4].
作用机制	The intramolecular disulfide bond can bind to the zinc ion in the active-site pocket of HDACs after romidepsin reduced to RedFK228 by cellular glutathione^[1].

CAS号	128517-07-7
分子式	C₂₄H₃₆N₄O₆S₂
分子量	540.7
SMILES Code	C/C=C(NC([C@@H](CSSCC/C=C/[C@@H](O1)CC2=O)NC([C@@H](C(C)C)N2)=O)=O)/C(N[C@@H](C(C)C)C1=O)=O
MDL No.	MFCD18433404

别名	FR 901228; FK 228; NSC 630176
运输	蓝冰

11z	3-100 nM	Kinase Assay		reduces HDAC enzymatic activity (IC50 = 6.5 ± 0.6 nmol/L)	20605144
1765-92		Growth Inhibition Assay		IC50=1.77 nM	18566246
402-91		Growth Inhibition Assay		IC50=1.26 nM	18566246
697		Growth Inhibition Assay		IC50 = 2.5 nM	21538216
697-R		Growth Inhibition Assay		IC50 = 8.6 nM	21538216
A549		Growth Inhibition Assay		IC50=1.26±0.24 nM	24954856
A549	10–100 nM	Growth Inhibition Assay	24/36/48 h	inhibits cell growth in both concentration- and time-dependent manner	24485799
A549	5 nM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth time-dependently	22106282
A549		Growth Inhibition Assay		IC50=3.24 nM	18566246
ACH-2	1-9 nM	Function Assay	24 h	induces HIV-1 Env expression	25149467
B104	2 nM	Function Assay	24/48/72 h	increases the surface expression of CD20	20686505
Brca1 Null	1–20nM	Growth Inhibition Assay	72 h	reduces cell viability alone and combined with cisplatin	23010348
Brca1 WT	1–20nM	Growth Inhibition Assay	72 h	reduces cell viability alone and combined with cisplatin	23010348
BT16	10 nM	Function Assay	24/48/72 h	increases CDKN1C expression	19221586
CA46		Apoptosis Assay	6 h	induces blunt apoptosis	23966164
CD4 T		Growth Inhibition Assay	48 h	EC50=4.5±1.0 nM	24722454
CD4 T		Growth Inhibition Assay	48 h	CC50=107±126 nM	24722454
CD4+ T		Growth Inhibition Assay		EC50=3 nM	24495105
CO115	5 nM-50 μM	Growth Inhibition Assay	24 h	inhibits cell growth in a concentration-dependent manner	22924958
DG75		Apoptosis Assay	6 h	induces no apoptosis	23966164
DpP75	1/10/100 nM	Apoptosis Assay	48 h	induces blunt apoptosis	23532732
DpVp35	1/10/100 nM	Apoptosis Assay	48 h	induces blunt apoptosis	23532732
DpVp50	1/10/100 nM	Apoptosis Assay	48 h	induces blunt apoptosis	23532732
DTC1		Growth Inhibition Assay		IC50=0.51 nM	18566246
EKVX		Growth Inhibition Assay		IC50=1.33±0.34 nM	24954856
Farage	2.5-15 nM	Cell Viability Assay	72 h	induces cytotoxicity in a concentration-dependent manner	25790907
FUJI		Growth Inhibition Assay		IC50=1.31 nM	18566246
G401	10 nM	Function Assay	24/48/72 h	increases CDKN1C expression	19221586
Granta-519	5-40 nM	Growth Inhibition Assay	24 h	IC50=58.5 nM	20068080
H146		Growth Inhibition Assay		IC50=0.22±0.07 nM	24954856
H460		Growth Inhibition Assay		IC50=2.58±0.80 nM	24954856
H526		Growth Inhibition Assay		IC50=0.15±0.03 nM	24954856
HA	0.625-10nM	Growth Inhibition Assay	48 h	induces a significantly stronger inhibition of cell proliferation co-treated with bortezomib	24771510
HBL-2	2-10 nM	Growth Inhibition Assay	24 h	IC50=4.3 nM	20068080
HCC95		Growth Inhibition Assay		IC50=2.5±0.05 ng/ml	19179890
HCT116	5-5000 nM	Growth Inhibition Assay	24 h	induces cell death in a concentration-dependent manner	25492515
HCT116		Growth Inhibition Assay		IC50=1.00±0.00 nM	24954856
HCT116	5 nM-50 μM	Growth Inhibition Assay	24 h	inhibits cell growth in a concentration-dependent manner	22924958
HCT116	20 nM	Function Assay	8 h	modulates transcript levels for hundreds of genes in either direction	20739454
HCT116-p21-/-		Growth Inhibition Assay		IC50=1.26±0.37 nM	24954856
HFS	5 nM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth time-dependently	22106282
HL60		Growth Inhibition Assay		IC50=1.86 nM	18566246
HL-60	1-500 nM	Cytotoxicity Assay	24 h	induces cytotoxicity in a concentration-dependent manner	20624163
HL-60	10 nM	Function Assay	4/6/16 h	induces the generation of hydrogen peroxide from 4h	20624163
HL-60	10-500 nM	Function Assay	4 h	decreases the histone deacetylase (HDAC) activity	20624163
hMSC-001F		Growth Inhibition Assay		IC50=>10 nM	18566246
HP100	1-500 nM	Cytotoxicity Assay	24 h	induces cytotoxicity in a concentration-dependent manner	20624163
HP100	10 nM	Function Assay	4/6/16 h	induces the generation of hydrogen peroxide from 4h	20624163
HP100	10-500 nM	Function Assay	4 h	decreases the histone deacetylase (HDAC) activity	20624163
Hs68		Growth Inhibition Assay		IC50=>10 nM	18566246
HuT78	1/10/100 nM	Apoptosis Assay	48 h	induces apoptosis at 1 nM	23532732
HUT78		Growth Inhibition Assay		IC50=1 nM	21198545
HuT-78		Growth Inhibition Assay		IC50=1.73±0.44 nM	24954856
Jeko-1	2-50 nM	Growth Inhibition Assay	24 h	IC50=11 nM	20068080
JJN3		Growth Inhibition Assay	24/48 h	EC50<1 nM; 48 h	24030150
JN-DSRCT-1		Growth Inhibition Assay		IC50=1.25 nM	18566246
KAO		Growth Inhibition Assay		IC50=0.91 nM	18566246
KM-H2	1 nM-100 μM	Cytotoxicity Assay	48 h	EC50=0.58 μM	19233470
L1236	1 nM-100 μM	Cytotoxicity Assay	48 h	EC50=0.07 μM	19233470
L428	1 nM-100 μM	Cytotoxicity Assay	48 h	EC50=0.43 μM	19233470
L540Cy	1 nM-100 μM	Cytotoxicity Assay	48 h	EC50=0.16 μM	19233470
LNCaP	5 nM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth time-dependently	22106282
LOX-IMVI		Growth Inhibition Assay		IC50=0.87±0.03 nM	24954856
LY7/EBV	2.5-15 nM	Cell Viability Assay	72 h	induces cytotoxicity in a concentration-dependent manner	25790907
MCF-10A		Growth Inhibition Assay		IC50=0.17±0.01 nM	24954856
MCF7		Growth Inhibition Assay		IC50=3.55 nM	18566246
MCF-7		Growth Inhibition Assay		IC50=1.10±0.20 nM	24954856
MDA-MB-231		Growth Inhibition Assay		IC50=0.68±0.14 nM	24954856
MDA-MB-435		Growth Inhibition Assay		IC50=0.90±0.06 nM	24954856
MMRU		Growth Inhibition Assay		IC50=2.57 nM	18566246
MS-275	0.625-10nM	Growth Inhibition Assay	48 h	induces a significantly stronger inhibition of cell proliferation co-treated with bortezomib	24771510
NCI/ADR-RES	1–20nM	Growth Inhibition Assay	72 h	reduces cell viability alone and combined with cisplatin	23010348
NCI-2882		Growth Inhibition Assay		IC50=1.6±0.04 ng/ml	19179890
NCI-H1299		Growth Inhibition Assay		IC50=4.6±0.2 ng/ml	19179890
NCI-H157		Growth Inhibition Assay		IC50=1.6±0.02 ng/ml	19179890
NCI-H1650		Growth Inhibition Assay		IC50=4.9±0.3 ng/ml	19179890
NCI-H1975		Growth Inhibition Assay		IC50=1.3±0.04 ng/ml	19179890
NCI-H23		Growth Inhibition Assay		IC50=2.9±0.2 ng/ml	19179890
NCI-H460		Growth Inhibition Assay		IC50=2.1±0.07 ng/ml	19179890
NCI-H820		Growth Inhibition Assay		IC50=2.4±0.1 ng/ml	19179890
NMS-2PC		Growth Inhibition Assay		IC50=0.81 nM	18566246
OCI-LY7	2.5-15 nM	Cell Viability Assay	72 h	induces cytotoxicity in a concentration-dependent manner	25790907
OPM-2		Growth Inhibition Assay	24/48 h	EC50s=1 nM; 48 h	24030150
OVCAR-3	4/8/16 nM	Growth Inhibition Assay	48 h	inhibits cell growth in a concentration-dependent manner	20404564
OVCAR-8	1–20nM	Growth Inhibition Assay	72 h	reduces cell viability alone and combined with cisplatin	23010348
PC3		Growth Inhibition Assay		IC50=1.65±0.35 nM	24954856
PC-3		Growth Inhibition Assay		IC50=2.51 nM	18566246
Ramos		Apoptosis Assay	6 h	induces extensive apoptosis	23966164
RKO	5 nM-50 μM	Growth Inhibition Assay	24 h	inhibits cell growth in a concentration-dependent manner	22924958
RPMI-8226		Growth Inhibition Assay	24/48 h	EC50s=1.8 nM; 48 h	24030150
S1		Growth Inhibition Assay		IC50=7.67±0.29 nM	24954856
SF-295		Growth Inhibition Assay		IC50=0.88±0.15 nM	24954856
SJSC	10 nM	Function Assay	24/48/72 h	increases CDKN1C expression	19221586
SK-BR-3		Growth Inhibition Assay		IC50=1.00±0.35 nM	24954856
SKNMC		Growth Inhibition Assay		IC50=1.17 nM	18566246
SKOV-3	1–20nM	Growth Inhibition Assay	72 h	reduces cell viability alone and combined with cisplatin	23010348
SKOV-3	4/8/16 nM	Growth Inhibition Assay	48 h	inhibits cell growth in a concentration-dependent manner	20404564
ST486		Apoptosis Assay	6 h	induces extensive apoptosis	23966164
STM91-01	10 nM	Function Assay	24/48/72 h	increases CDKN1C expression	19221586
SU-CCS-1		Growth Inhibition Assay		IC50=0.89 nM	18566246
SU-DHL4	2.5-15 nM	Cell Viability Assay	72 h	induces cytotoxicity in a concentration-dependent manner	25790907
SW480		Growth Inhibition Assay		IC50=2.69 nM	18566246
SW620		Growth Inhibition Assay		IC50=0.93±0.29 nM	24954856
SYO-1		Growth Inhibition Assay		IC50=0.67 nM	18566246
THJ-16T	1 nM	Growth Inhibition Assay	24 h	inhibits cell growth	20810568
U266		Growth Inhibition Assay	24/48 h	EC50s=10 nM; 48 h	24030150
U2932	2.5-15 nM	Cell Viability Assay	72 h	induces cytotoxicity in a concentration-dependent manner	25790907
U2932/EBV	2.5-15 nM	Cell Viability Assay	72 h	induces cytotoxicity in a concentration-dependent manner	25790907
UACC-62		Growth Inhibition Assay		IC50=0.56±0.16 nM	24954856

Romidepsin/罗米地辛 {[allProObj[0].p_purity_real_show]}

Romidepsin/罗米地辛纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Romidepsin/罗米地辛质控信息

Romidepsin/罗米地辛生物活性

Romidepsin/罗米地辛细胞实验

Romidepsin/罗米地辛动物实验

Romidepsin/罗米地辛动物研究

Romidepsin/罗米地辛临床研究

Romidepsin/罗米地辛参考文献

Romidepsin/罗米地辛实验方案

Romidepsin/罗米地辛技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Romidepsin/罗米地辛 {[allProObj[0].p_purity_real_show]}

Romidepsin/罗米地辛 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Romidepsin/罗米地辛 质控信息

Romidepsin/罗米地辛 生物活性

Romidepsin/罗米地辛 细胞实验

Romidepsin/罗米地辛 动物实验

Romidepsin/罗米地辛 动物研究

Romidepsin/罗米地辛 临床研究

Romidepsin/罗米地辛 参考文献

Romidepsin/罗米地辛 实验方案

Romidepsin/罗米地辛 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Romidepsin/罗米地辛纯度/质量文件产品仅供科研

Romidepsin/罗米地辛质控信息

Romidepsin/罗米地辛生物活性

Romidepsin/罗米地辛细胞实验

Romidepsin/罗米地辛动物实验

Romidepsin/罗米地辛动物研究

Romidepsin/罗米地辛临床研究

Romidepsin/罗米地辛参考文献

Romidepsin/罗米地辛实验方案

Romidepsin/罗米地辛技术信息